Show simple item record

dc.contributor.authorCochran, Sam
dc.contributor.authorHussen, Nebat
dc.contributor.authorMartin, Elise
dc.contributor.authorRaji, Yazdan
dc.contributor.authorTran, Lynn
dc.date.accessioned2016-05-11T17:10:26Zen
dc.date.available2016-05-11T17:10:26Zen
dc.date.issued2016-05en
dc.identifier.urihttp://hdl.handle.net/10675.2/609063en
dc.descriptionCritically appraised topic completed as an assignment in Essentials of Clinical Medicine IIen
dc.description.abstractDoes treatment with sofosbuvir for Hepatitis C genotype 2 or 3 patients for whom peginterferon and ribavirin treatment was not an option lead to a sustained virologic response at 12 week weeks after therapy?
dc.language.isoen_USen
dc.relation.ispartofseriesSpringen
dc.relation.ispartofseries2016en
dc.subjectRandomized Controlled Trialen
dc.subjectHepacivirusen
dc.subjectHepatitis C, Chronicen
dc.subjectDrug Therapy, Combinationen
dc.subjectTreatment Outcomeen
dc.titleSofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsen_US
dc.typeOtheren
dc.contributor.departmentMedical College of Georgiaen
refterms.dateFOA2019-04-09T22:51:16Z
html.description.abstractDoes treatment with sofosbuvir for Hepatitis C genotype 2 or 3 patients for whom peginterferon and ribavirin treatment was not an option lead to a sustained virologic response at 12 week weeks after therapy?


Files in this item

Thumbnail
Name:
CAT_Cochran_2016.pdf
Size:
160.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record